JP2023508328A5 - - Google Patents
Info
- Publication number
- JP2023508328A5 JP2023508328A5 JP2022538220A JP2022538220A JP2023508328A5 JP 2023508328 A5 JP2023508328 A5 JP 2023508328A5 JP 2022538220 A JP2022538220 A JP 2022538220A JP 2022538220 A JP2022538220 A JP 2022538220A JP 2023508328 A5 JP2023508328 A5 JP 2023508328A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- cancer
- pharmaceutically acceptable
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952039P | 2019-12-20 | 2019-12-20 | |
| US62/952,039 | 2019-12-20 | ||
| PCT/US2020/065409 WO2021127044A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508328A JP2023508328A (ja) | 2023-03-02 |
| JP2023508328A5 true JP2023508328A5 (enExample) | 2023-12-26 |
| JP7631348B2 JP7631348B2 (ja) | 2025-02-18 |
Family
ID=76478095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538220A Active JP7631348B2 (ja) | 2019-12-20 | 2020-12-16 | 組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230008362A1 (enExample) |
| EP (1) | EP4069235A4 (enExample) |
| JP (1) | JP7631348B2 (enExample) |
| KR (1) | KR20220119442A (enExample) |
| CN (1) | CN115427042A (enExample) |
| AU (1) | AU2020407070A1 (enExample) |
| BR (1) | BR112022012281A2 (enExample) |
| CA (1) | CA3165472A1 (enExample) |
| IL (1) | IL294080A (enExample) |
| MX (1) | MX2022007626A (enExample) |
| TW (1) | TW202132299A (enExample) |
| WO (1) | WO2021127044A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| EP4431511A4 (en) * | 2021-11-09 | 2025-10-15 | Hangzhou Glubio Pharmaceutical Co Ltd | WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017517520A (ja) | 2014-05-29 | 2017-06-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| KR20200108301A (ko) * | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
-
2020
- 2020-12-16 AU AU2020407070A patent/AU2020407070A1/en active Pending
- 2020-12-16 CA CA3165472A patent/CA3165472A1/en active Pending
- 2020-12-16 IL IL294080A patent/IL294080A/en unknown
- 2020-12-16 CN CN202080095235.7A patent/CN115427042A/zh active Pending
- 2020-12-16 WO PCT/US2020/065409 patent/WO2021127044A1/en not_active Ceased
- 2020-12-16 KR KR1020227025073A patent/KR20220119442A/ko not_active Ceased
- 2020-12-16 JP JP2022538220A patent/JP7631348B2/ja active Active
- 2020-12-16 US US17/757,493 patent/US20230008362A1/en not_active Abandoned
- 2020-12-16 BR BR112022012281A patent/BR112022012281A2/pt unknown
- 2020-12-16 MX MX2022007626A patent/MX2022007626A/es unknown
- 2020-12-16 EP EP20902208.6A patent/EP4069235A4/en active Pending
- 2020-12-18 TW TW109145139A patent/TW202132299A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508328A5 (enExample) | ||
| JP2023508332A5 (enExample) | ||
| JP2021516242A5 (enExample) | ||
| JP7348906B2 (ja) | フェロトーシス誘導活性を有する化合物およびそれらの使用方法 | |
| CN101941970B (zh) | 用于治疗癌症的meleimide衍生物、药物组合物以及方法 | |
| JP2020517616A5 (enExample) | ||
| JP2024530495A5 (enExample) | ||
| RU2007134396A (ru) | Химические соединения | |
| JP2023507797A5 (enExample) | ||
| RU2693404C2 (ru) | Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP7759877B2 (ja) | 治療用化合物 | |
| JP2023526283A5 (enExample) | ||
| RU2008126245A (ru) | Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| AU2019397481B2 (en) | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same | |
| JP2023508327A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| RU2020102453A (ru) | Фармацевтические композиции | |
| RU2013107007A (ru) | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение | |
| JP2006519862A5 (enExample) | ||
| CN108431000A (zh) | 作为dna甲基转移酶抑制剂的新型化合物 | |
| TW202116770A (zh) | 類鐸受體促效劑 | |
| JP2022521818A5 (enExample) | ||
| JPWO2020032105A5 (enExample) | ||
| JP2024125139A5 (enExample) |